From DCAT Value Chain Insights (VCI)
Juniper Pharmaceuticals, a women's-health therapeutics company based in Boston, Massachusetts, has appointed Alicia Secor as its president and chief executive officer (CEO), effective on August 1, 2016. Ms. Secor will also be appointed to the company’s Board of Directors. She succeeds Frank Condella, who announced his intent to retire as Juniper's president and CEO earlier this year.
Ms. Secor brings more than 25 years' of leadership experience as a life-sciences executive. She joins Juniper from Zafgen, a biopharmaceutical company also based in Boston, where she served as chief commercial officer. Previously she served 15 years at Genzyme in diverse leadership roles, most recently as the global general manager for the metabolic disease business. Prior to Genzyme, Ms. Secor held positions at Alkermes in business development, at Centocor (a Johnson & Johnson Company) in clinical and commercial operations, and began her career at Pfizer as a hospital-based sales representative.
Source: Juniper Pharmaceuticals
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription